CYP2D6 and CYP1A1 mutations in the Turkish population

Related Experiment Video

Updated: Aug 20, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Muge Aydin1, Ozden Hatirnaz, Nevin Erensoy

  • 1Department of Genetics, Institute for Experimental Medicine (DETAE), Istanbul University, Istanbul, Turkey.

Cell Biochemistry and Function
|January 14, 2005
PubMed

Insights

This study investigated genetic variations in cytochrome P450 enzymes (CYP1A1 and CYP2D6) in Turkish individuals. Findings reveal specific mutant allele frequencies, crucial for understanding cancer susceptibility and drug response in this population.

Area of Science:

  • Pharmacogenomics
  • Molecular Epidemiology
  • Cancer Research

Background:

  • Metabolic enzymes like cytochrome P450 (CYP) and glutathione S-transferases metabolize drugs and carcinogens.
  • Functional polymorphisms in genes encoding these enzymes influence individual cancer susceptibility and drug response.
  • Molecular insights into these polymorphic enzymes aid in understanding cancer etiology and clinical therapeutic management.

Purpose of the Study:

  • To determine the genotype and allele frequencies of cytochrome P450 1A1 (CYP1A1) and 2D6 (CYP2D6) variants in the Turkish population.
  • To establish baseline data for CYP1A1 and CYP2D6 mutant allele distributions in Turkish individuals.
  • To provide foundational data for epidemiological studies correlating therapeutic strategies and cancer etiology in Turkish patients.

Main Methods:

  • Genotyping of CYP1A1 and CYP2D6 variants was performed using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique.
  • Analysis included a cohort of 140 Turkish individuals.
  • Allele and genotype frequencies were calculated for specific CYP1A1 and CYP2D6 polymorphisms.

Main Results:

  • The frequency of the CYP1A1*2A mutant allele was observed to be 15.4%.
  • Frequencies of the CYP2D6*3 and CYP2D6*4 mutant alleles (associated with poor metabolizer phenotype) were 2.5% and 13.9%, respectively.
  • This study reports the initial distribution data for CYP1A1 and CYP2D6 mutant alleles within the Turkish population.

Conclusions:

  • This research presents the first comprehensive data on CYP1A1 and CYP2D6 mutant allele frequencies in the Turkish population.
  • The established allele frequencies are essential for future epidemiological studies on cancer etiology and personalized medicine in Turkey.
  • Understanding these genetic variations can inform therapeutic approaches and improve cancer management strategies for Turkish patients.

More Related Videos

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...